Parkinson 'plus';Parkinson 'plus'

Revue du Praticien

Volumn 47, Issue 10, 1997, Pages 1077-1082

  Fabre, Nelly ^a   Brefel Courbon, Christine ^a   Rascol, Olivier ^a  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; ANTIPARKINSON AGENT;

BRAIN ATROPHY; DISEASE CLASSIFICATION; DRUG EFFICACY; HUMAN; PARKINSON DISEASE; SHORT SURVEY; SHY DRAGER SYNDROME; ARTICLE; CLASSIFICATION; NEUROLOGIC DISEASE; SENSITIVITY AND SPECIFICITY;

ANTIPARKINSON AGENTS; HUMANS; LEVODOPA; NERVOUS SYSTEM DISEASES; PARKINSON DISEASE; SENSITIVITY AND SPECIFICITY;

EID: 0030925455     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (21)

1. Hughes AJ, Daniel SE, Kilford L, Lees A. The accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study. J Neurol Neurosurg Psychiatr 1992; 55: 181-4.
2. Quinn N. Multiple system atrophy-the nature of the beast. J Neurol Neurosurg Psychiatr 1989; SS: 78-89.
3. Lees AJ. The Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). In: Marsden CD, Fahn S (eds). Movement Disorders 2. London: Butterworths, 1990: 272-87.
4. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy: a heterogeneous degeneration involving the brainstem, basal ganglia and cerebellum, with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964; 10: 333-59.
5. Vidailhet M, Rivaud S, Gouider-Khouja N et al. Eye movements in Parkinsonian syndromes. Ann Neurol 1994; 35: 420-6.
6. Cambier J, Masson M, Viader F, Limodin J, Strube A. Le syndrome frontal de la paralysie supranucléaire progressive. Rev Neurol 1985; 141: 528-36.
7. Blin J, Baron JC, Dubois B et al. Positron emission tomography study in progressive supranuclear palsy; brain hypometabolic pattern and clinicometabolic correlations. Arch Neurol 1990; 47: 747-51.
8. Nieforth KA, Golbe LI. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol 1993; 16: 338-46.
9. Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multisystem atrophy. J Neurol Neurosurg Psychiatr 1969; 32: 28-34.
10. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy Drager syndrome). J Neurol Sci 1989; 94: 79-100.
11. Costa C, Duychaerts C, Cervera P, Hauw JJ. Les inclusions oligodendrogliales, ou marqueurs des atrophies multisystématisées. Rev Neurol 1992; 148: 274-80.
12. Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension = a clinical-pathological study. Arch Neurol 1960; 2: 511-27.
13. Van Engelghem, Van Zandijcke, Lammens M. Pure antomomic failure: a new case with clinical, biochemical and necropsy data. J Neurol Neurosurg Psychiatr 1994; 57: 745-7.
14. Dubas F, Vidailhet M, Henin D. Syndrome parkinsonien peu réactif à la dopathérapie chez un homme de 64 ans. Rev Neurol 1992; 148: 580-5.
15. Rascol O, Sabatini U, Fabre N et al. Abnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease. Mov Dis 1995; 10: 163-70.
16. Hughes AJ, Colosimo C, Kleedorfer B, Daniel SE, Lees AJ. The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatr 1992; 55: 1009-13.
17. Senard JM, Montastruc JL. Which drug for which orthostatic hypotension. Fundam Clin Pharmacol 1996; 10: 225-33.
18. Gibb WRG. Neuropathology in movement disorders. J Neurol Neurosurg Psychiatr, 1989; SS: 55-67.
19. Rinne JO, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration. A clinical study of 36 cases. Brain 1994; 117: 1183-96.
20. Crystal HA, Dickson DW, Lizardi JE, Davies P, Wolfson LI. Antemortem diagnosis of diffuse Lewy body disease. Neurology 1990; 40: 1523-8.
21. Bordet R, Destee A. De la maladie de Parkinson à la maladie des corps de Lewy. Presse Med 1992; 21: 708-12.